Introduction The flow diverter is a unique and important tool in the endovascular treatment of aneurysms. However, its use requires patients to be on dual antiplatelet therapy to prevent thromboembolic complications. The duration of dual antiplatelet therapy has not been standardized due to the relative risks of thromboembolic (too short) and hemorrhagic (too long) complications. The objective of this study is to compare the thromboembolic and hemorrhagic complication rates of patients on a shorter versus a longer course of dual antiplatelet therapy.
Methods Patients undergoing flow diversion were prospectively enrolled in an institutional registry. After 3 to 6 months of dual antiplatelet therapy, patients were converted to aspirin 325 mg up to the 12 month period. Patients on dual antiplatelet therapy for <100 days were included in the short cohort while those on dual antiplatelet therapy for ≥100 days were included in the long cohort. The proportions of thromboembolic and hemorrhagic complications in these respective cohorts were compared using the Fisher’s exact test.
Results A total of 110 cases were eligible (mean age: 56.7 years). The majority were female (81.8%) and received the Pipeline Embolization Device (83.6%). 7.3% of patients presented with ruptured aneurysms. More than 1 flow diverter was required in 7.3% of cases. The majority (90.9%) of the dual antiplatelet regimen involved aspirin 325 mg and clopidogrel 75 mg. Most patients were on dual antiplatelet therapy between 3–6 months in duration prior to transitioning to aspirin monotherapy (325 mg). In the shorter duration cohort, the thromboembolic complication rate was 9.3% compared to 12.5% in the longer duration cohort (p=0.76). Similarly, the hemorrhagic complication rate was 5.6% in the short duration cohort compared to 14.3% in the longer duration cohort (p=0.20).
Conclusion A shorter duration of dual antiplatelet therapy after flow diversion was not associated with a higher thromboembolic complication rate. While the duration of antiplatelet therapy should be personalized for each patient, transitioning to monotherapy after 3 months is likely safe.
Disclosures V. Ban: None. M. Pernik: None. T. Binyamin: None. J. Corona: None. Y. Kim: None. R. de Oliveira Sillero: None. R. Novakovic: None. G. Pride: None. J. Barr: None. J. White: None. H. Batjer: None. B. Welch: 2; C; Medtronic, Stryker, MicroVention. 6; C; Peter Lazic.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.